Latest / Psychopharmacology Today / Ep. 9: Three Current Transformations in Psychiatry (and Their Implications)
Transcript
- 0:05We're very happy to have Dr.
- 0:06Jim Phelps with us.
- 0:07Dr.
- 0:07Phelps focused his psychiatric practice on complex mood disorders for over 20 years.
- 0:13He served on the International Society for Bipolar Disorders, Diagnosis, and Chronotherapy Task Forces.
- 0:19He founded the website, psycheducation.org, in 2000, and recently a simpler, shorter version, depressioneducation.org, leading to book invitations, "Why Am I Still Depressed?
- 0:31for Patients and Families" and "A Spectrum Approach to Mood Disorders for Professionals." Currently, Dr.
- 0:36Phelps is completing a series on YouTube at Psych Education, presenting the same material in 30 five-minute videos.
- 0:44He is a co-creator of "Brainstorm: The Film,"
- 0:47a documentary on the bipolar spectrum premiered at World Bipolar Day in 2026 and scheduled for the national PBS airing in 2027.
- 0:57So welcome, Dr.
- 0:58Phelps.
- 0:58Thank you very much, Jeff.
- 0:59And thank you very much everyone for taking some time.
- 1:02I'll try to make it worth your while.
- 1:03As Jeff mentioned, I'm with the ISBD as a member for quite some time.
- 1:08I'm sort of a closet academic.
- 1:09I've written a bunch of stuff, but it's really based on clinical experience and I hope to share that perspective with you now.
- 1:16So when someone tells you why they should listen to you, you should tell them why they shouldn't.
- 1:21Here are the reasons why you might keep your skeptic's hat on.
- 1:24I will mention a couple of things for which I get no money at all: the education website and the YouTube channel.
- 1:30And I'll show you, there's one more opportunity to see "Brainstorm" before it goes to public television.
- 1:37And I'll give you the dates and how to access it at the end here.
- 1:40So I'm gonna talk about three transformations in psychiatry.
- 1:43I think this is really exciting.
- 1:45I hope you'll find it interesting and
- 1:47I hope actually potentially changing the way you practice.
- 1:50That's why you're here, I hope.
- 1:51So I think the psychiatric diagnostic system is poised to potentially change.
- 1:56I'll show you how.
- 1:57I think we're making clear progress on understanding the mechanisms of psychiatric illness, at least bipolar disorders, which are leading to new treatment opportunities.
- 2:06So I think that's very exciting.
- 2:08And then you've probably heard the notion of using very low doses of lithium for the potential prevention of dementia.
- 2:14And I'll show you some of those data, why I'm so excited about it, for changing the reputation of lithium, at minimum.
- 2:21As potentially prescribing psychologists, I hope that lithium is part of your armamentarium.
- 2:26If it's not, I hope to make it so.
- 2:28And if it already is, but you are
- 2:30having difficulty getting patients to accept it, I think these data could change that now.
- 2:36So here we go.
- 2:37The diagnostic system is changing.
- 2:39Well, imagine if Sandra comes in to see you as your next new client with depression.
- 2:45According to the DSM, the first thing you're supposed to do, or one of the many things, is to see if this depression is unipolar or bipolar, because of course, even Bipolar I can
- 2:55present with
- 2:56what looks like major depression.
- 2:57In order to establish how common is that, and I'd like you to ponder, well, how often do you think depression coming into your practice, like Sandra, is actually bipolar?
- 3:09How common is that?
- 3:10Of course, it depends on how you practice and what your referrals are like, but you ought to know what the base rate is in the general population.
- 3:17That'll help you understand at minimum what your estimates might be.
- 3:21So base rate estimates...
- 3:24You might know this book from Daniel Kahneman, are not common in the way people estimate the frequency of something like how common is bipolar.
- 3:34This book, the "Fast and Slow" book, came from the technical, the formal book that he wrote with Amos Tversky called "Judgment Under Uncertainty." Magnificent book, very old
- 3:43now.
- 3:44But one of the biases that they present there is what they call "base rate neglect."
- 3:50So let's not do base rate neglect.
- 3:52Let's start by looking at base rates in the general population for mood disorders of all kinds or the variations of depression, let's say.
- 4:00So what are those base rates?
- 4:01We should look at large epidemiologic studies to give us some actual numbers on that.
- 4:06And if we took a hundred depressed Sandras, (using that to make the math easier) it turns out that using those large epidemiologic studies,
- 4:14there would be 80 depressed Sandras in the unipolar department and five in the Bipolar I land.
- 4:22So five out of a hundred, that's amongst people who are presenting with depression, like Sandra.
- 4:28Well, you might wonder where are the other folks?
- 4:31And so another five of them are depression with hypomania or Bipolar II, but we still have some missing people.
- 4:39And so these data are coming from some major epidemiologic studies in the US and abroad, where they also looked at subthreshold bipolarity or the bipolar spectrum.
- 4:50And lo and behold, there's another 10% of people who have subthreshold hypomania in these telephone survey, answer-these-questions-please, format of detecting what kind of
- 5:02depression do you have and mixed states, particularly mixed states if we start to
- 5:06expand the definition of mixed states as has recently been done.
- 5:10So, what does this mean, these numbers?
- 5:13Well, for one thing, means that bipolarity is about a one in five probability if you didn't have anything in your practice to select a higher probability of bipolar, like if
- 5:25you take complex depressions,
- 5:28that's probably a higher number like one in four, which that one in four number can easily be justified even with these data.
- 5:35I've given you the conservative numbers for this.
- 5:38In other words, bipolar as a possibility when Sandra presents with depression is definitely a probability.
- 5:48And in your practice, it ought to be something on the order of one in five,
- 5:52unless somehow your practice elects away people with bipolar and that's quite possible as well, in which case it might go down to as low as one in 10, but I doubt much below that.
- 6:03Well, you might be thinking, "Well, yeah, but suppose this subthreshold hypomania and mixed states, what does that mean for treatment?
- 6:09Or do we really treat those differently than in unipolar?" The answer is, from my point of view, yes, it means that
- 6:15We should be avoiding antidepressants more likely in these people than we do for unipolar.
- 6:21We should be thinking more likely to use soco rhythm therapy.
- 6:25And I'll present you some data on SRT to make it part of your kit bag, your toolkit, if you don't already have it there, and Lamotrigine.
- 6:34So, not antidepressants and thinking about these other potential antidepressants that have mood-stabilizing capacity as well.
- 6:42So when Sandra comes in, then you're not thinking bipolar or unipolar, you're thinking where on this spectrum is Sandra?
- 6:49How much bipolarity does she have?
- 6:52And could she be somewhere here in the middle?
- 6:55Well, I think you probably know from clinical experience, to rule out hypomania and particularly to rule out subthreshold hypomania and mixed states is a major time-consuming
- 7:08endeavor.
- 7:09In fact, it's really hard to say
- 7:11I've done it and it's not there.
- 7:13You can say I've done it, but to say for certain that it's not there is extremely challenging.
- 7:19I think some people might say near-impossible.
- 7:22So I'm gonna show you a different way of thinking about that now that's coming maybe for us in the next DSM.
- 7:28Remember, this is transformation number one.
- 7:31I'm sorry, I need to make the picture worse for you first, because
- 7:35not only is there a spectrum of mood, there is also a spectrum of anxiety.
- 7:4050% of people with mood disorders have DSM-diagnosable level anxiety, and that anxiety itself exists on a spectrum.
- 7:49So really what we should have is a three-dimensional model, three axes that looks like this.
- 7:56A person could be in euthymia, but have anxiety.
- 8:00Person could be heading toward mania and also have anxiety
- 8:03or poor depression and also have anxiety or really any admixture.
- 8:09So this is the reality that you're faced clinically, including when you see Sandra, as she shows up in your practice.
- 8:16And this has been acknowledged by mood specialists for years, but the DSM doesn't work like this.
- 8:23The DSM says you either have this or you have that or you have that.
- 8:28So we are missing the subtlety of
- 8:31all these other people who exist in intermediate states between these poles of diagnoses.
- 8:37And what's exciting about the new DSM discussions is that they are potentially going to change, it isn't for sure yet, and move from, here's the jargon terminology, move from a
- 8:50categorical system of the DSM to a dimensional, or at least include a dimensional way, "dimensional" is the jargon term for
- 9:00"spectrum," include a spectrum way of thinking about mood and anxiety like this.
- 9:06This was first published in January of this year.
- 9:11There's a subcommittee that's looking at including this dimensional way of thinking about diagnoses.
- 9:16And they said that patients are distributed smoothly from low to high numbers across dimensions
- 9:22without leaving clear gaps between clusters.
- 9:26In other words, they're describing this.
- 9:29They also said that in redesigning the DSM structure, they intend to capture both categorical and dimensional constructs.
- 9:37In other words, we aren't going to abandon the categorical way of thinking, but if this team that's looking at the next DSM gets its way, they will include
- 9:47a dimensional approach as well.
- 9:49So we can think more flexibly about, well, diagnostically, where is Sandra in this at least three-dimensional map?
- 9:57We could include some other dimensions like psychosis, how psychotic, I mean, go off in a fourth dimension, but I couldn't map that one for you.
- 10:05So we'll leave it like this for now.
- 10:08Well, what are the implications of this potential change in the DSM?
- 10:11Firstly, and if you think of nothing else from this evening, if it hasn't already been your conclusion, I invite you to conclude that uncertainty about diagnoses, in this
- 10:21territory, is wisdom.
- 10:24That's the kind way of putting it.
- 10:25The less-polite way of putting it would be, to be certain about something is imprudent, shall we say.
- 10:32So, you know, when I'm working with trainees and I hear someone say, "Oh, no, she doesn't have bipolar disorder."
- 10:38It's like, well, wait a minute, how do you know that?
- 10:40You should not be so certain about that really ever until you know, clinical courses proving that, you know, mood instability is not part of the picture.
- 10:50So it isn't that you'll stay uncertain forever, but especially with a client's initial presentation, coming out of that initial interview with uncertainty is wisdom in this
- 11:01territory.
- 11:02This
- 11:03is actually making its way into the literature now with the terminology that you may run into called "epistemic humility." Epistemology, theory of knowledge, recognizing that it's
- 11:13hard to know things for certain, epistemic humility.
- 11:16And then another implication of this potential DSM change is that the Rapid Mood Screener, which I'm sure you've heard of and some of you may be using, well, it's a categorical
- 11:28tool.
- 11:28It's a yes or no tool.
- 11:30The questions are yes or no.
- 11:32The supposed cutoff at four or more is a yes or no system.
- 11:37Well, that really is not compatible with this dimensional way of thinking.
- 11:41And it's actually not a good way of thinking about screening at all anyway, because there are so many people with subthreshold presentations and that tool was actually developed
- 11:51specifically for Bipolar I.
- 11:53So when
- 11:55your clients are presenting like Sandra, it's actually much more likely that if they have a bipolar variation, it's going to be one of these non-manic versions, statistically.
- 12:06So we should be using a screening tool that can capture them.
- 12:09And not having a 32% rate of false negatives for Bipolar II, as it did in the 2nd validation trial where they included people with Bipolar II.
- 12:18So if you're going to use the RMS, you should modify it for greater sensitivity.
- 12:23And I won't go into great detail about this, but we did manage to get this editorial published.
- 12:28And here is a modified RMS.
- 12:31And I will show you in a moment where to go get it.
- 12:33The difference here is that we have set the thresholds at previously accepted thresholds, not for Bipolar I, but for all versions of bipolar, including using
- 12:44Bipolar II thresholds for duration, for example, four days instead of seven.
- 12:48So this modified RMS, modified to increase its sensitivity, you can find that on my depressioneducation website.
- 12:55I don't make any money from this website.
- 12:57It doesn't sell anything.
- 12:58But if in the search term, it's in the search bar up there on the top, you put in "RMS," you'll find a bunch of different variations, PDFs and Word versions that you can change,
- 13:09and a little description of the RMS itself at the bottom.
- 13:13So if you're gonna use an RMS, use this.
- 13:16We're moving on to our second
- 13:18of these three big transformations in psychiatry from my point of view.
- 13:22And that is that we are making progress on understanding the mechanisms of at least one psychiatric illness.
- 13:28And I think several, but bipolar in particular, let me show you.
- 13:32So I hope you've puzzled over this.
- 13:35What causes this thing that can be like, you know, a manic presentation or a depressive presentation?
- 13:40From one problem, presumably one problem?
- 13:43How can that be?
- 13:45Well, here are some insights into that from recent research.
- 13:49There are five of these that are major pathways in terms of understanding the mechanism of bipolar.
- 13:55I'll just gloss over, hit the high points on four of them, and then I'm gonna focus on one of them because it's most directly tied to a treatment tool that you may not be currently
- 14:05using or emphasizing.
- 14:07So genetics, well, it's genetic for sure.
- 14:10It's the most highly heritable of psychiatric disorders.
- 14:13On the other hand, genetics is not absolute prognosis because it's hard to tell.
- 14:18It's not a fate predictor.
- 14:20Even people who are carrying the genes that are now being identified for bipolar won't necessarily find them expressed in terms of behavior and experience because of epigenetic
- 14:30changes
- 14:30superimposed on those genes.
- 14:32So we're learning more about the particular genes involved, and part of the answer here is that yeah, there's a bunch of them.
- 14:38But a few of them are starting to be identified that have more clout.
- 14:41So we're getting in the direction maybe of being able to predict for people what's the probability that your offspring, for example, is vulnerable or how vulnerable.
- 14:50Inflammation is now clearly recognized as part of
- 14:54mood disorders in the brain, and inflammatory factors from the gut can get to the brain through several different channels.
- 15:01So thinking about gut inflammation and inflammation generally is a new whole avenue in terms of thinking about treatment.
- 15:08Metabolism, both peripheral and brain metabolism, is also clearly a pathway into bipolar symptoms.
- 15:16You've probably heard about the ketogenic diet, helping people shift away from their brain burning glucose as a fuel to burning ketones, the fat backup to glucose, as a fuel, and
- 15:28doing that through dietary changes that make it difficult to
- 15:32get the glucose supply to your brain.
- 15:34So instead people's brains switch to burning ketones.
- 15:38And lo and behold, that has helped people come completely out of psychosis and stay psychosis-free on multiple case reports.
- 15:46We're still in the realm of case reports almost entirely.
- 15:50There is a small randomized trial showing that this does have feasibility, but efficacy relative to a SHMP procedure,
- 16:00we don't have a big trial for that.
- 16:01And what is clear is that it is a challenge for people to stick with a ketogenic diet.
- 16:06So that's exciting, but not clearly ready for primetime treatment applicability yet, except for maybe a highly motivated subset, particularly those who had like
- 16:17treatment-resistant psychosis.
- 16:19It's another plausible tool to consider even right now.
- 16:23What's also clear in metabolism is that mitochondria, there's something different about people's mitochondria, those who are living with bipolar.
- 16:30And that, in part, helps explain why when people are depressed with bipolar depression, energy, a profound lack of energy, it's not just a depression, it is something wrong with
- 16:42your mitochondria; you can't move kind of depression.
- 16:46And then some fascinating stuff going on in the realm of psychology with reward sensitivity.
- 16:51The very short version being this young man who's looking at his cards.
- 16:56People living with bipolar looking at those cards have a higher likelihood of thinking that when they bet, they're going to get the good outcome.
- 17:07So
- 17:07a reward hypersensitivity, a tendency to latch on to the potential for reward and overestimate it, is part of the bipolar experience in the world, even during euthymia.
- 17:19Moreover, we know from the work of a remarkable team at the University of Pittsburgh, where in the brain that overestimation takes place: in the left
- 17:30ventrolateral prefrontal cortex.
- 17:32And it's so localized that they've even used a transcranial magnetic stimulation device over that left ventrolateral prefrontal cortex using not the stimulating mode of TMS, but
- 17:45the inhibiting mode, one cycle per second instead of 10, which can damp down neuronal activity directly underneath the wand.
- 17:54And lo and behold, damping down that
- 17:57tendency to overestimate reward.
- 17:59But you don't have to do this with TMS.
- 18:01You could do this with cognitive therapy, which is also being explored by the Pittsburgh team.
- 18:06So what if you just teach this young man, "You have a proclivity to overestimate the probability of reward in this setting, you should be careful.
- 18:14You should also be careful about what that other guy has behind his back.
- 18:17But at least in your own brain, you can work on your own proclivity."
- 18:20That's reward hypersensitivity in a tiny little nutshell.
- 18:24And now I'm going to turn to the biological clock differences because these have a direct treatment implication that I hope you're applying even now.
- 18:31Let's see.
- 18:32So you know about the biological clock and how it governs all of these physiologic cycles.
- 18:38And you know that what the biological clock amounts to is an internal signal.
- 18:42For most people around 24 hours, some people it's a little more like 25, saying to your body, this is day, this is night.
- 18:51Well, people with bipolar, people living with bipolar have a different clock.
- 18:56It tends instead
- 18:58to have a lower amplitude of the magnitude of this internal signal.
- 19:03This is day and this is night.
- 19:06So the immediate treatment implication then is that if we could just strengthen that circadian rhythm, that this would have a mood stabilizing effect.
- 19:17And this has been demonstrated in a number of different ways.
- 19:20So the question then in terms of turning this into practice is how do you strengthen circadian rhythm?
- 19:26Well, I'm sure that's
- 19:27probably quite well known to you.
- 19:29What is the strongest factor?
- 19:30The zeitgeber, the time giver that sets circadian rhythm?
- 19:35It's light and darkness.
- 19:37So people living with bipolar, to get another mood stabilizer on board, could use the strengthening of their circadian rhythm, including doing so by getting more light when it
- 19:49should be light and more darkness when it should be dark.
- 19:53Wait a minute...
- 19:53You've already done this.
- 19:54And you've discovered that trying to convince people to get more darkness when it should be dark is a behavioral challenge.
- 20:02Because bedtime comes when it should already have been dark for quite some time, right?
- 20:08What's natural is for it to be dark when the sun goes down.
- 20:11And yet we in our modern, electronically lit environments are getting light long through that period when it should be dark.
- 20:18So
- 20:19just telling people, "You shouldn't use those electronics and stay up late watching television." Well, you know what it's like trying to sell that idea.
- 20:28It just doesn't go over very well.
- 20:29Ah, but you can cheat!
- 20:32You can use a virtual darkness.
- 20:34So I'll just tell you briefly the story that I think many of you have heard, but you may not have seen the physiologic pathway of it.
- 20:40Light affects our circadian rhythm, not through rods and cones,
- 20:47but through another retinal photoreceptor called the retinal ganglion cell.
- 20:51Its fibers do not connect to the visual cortex.
- 20:54They go instead to the hypothalamus, to the suprachiasmatic nucleus of the hypothalamus, where among many other things, the hypothalamus tells the pineal gland, don't secrete
- 21:05melatonin just now because we are in a lit environment.
- 21:09Well, it turns out, and here's the key to the whole thing, that not all wavelengths of light are equal;
- 21:15that only blue light stimulates the retinal ganglion cells.
- 21:19And so you can have artificial darkness simply by blocking blue light, because no blue light reaching the retinal ganglion cell is the physiologic equivalent of darkness.
- 21:31And you can show that because under the right circumstances, namely when the rest of the circadian rhythm says it should be dark and time to secrete melatonin by, even in a fully
- 21:41lit environment,
- 21:42blocking blue light, melatonin is secreted just as it should be.
- 21:45Well, how do you block blue light?
- 21:47You've heard of these amber lenses, blue blockers.
- 21:50And so there are a number of physiologic studies showing that this whole pathway works just as I've just described.
- 21:56So when I discovered this many years ago, I said, hey, you know, I wonder if we could use this for bipolar,
- 22:02because we could do dark therapy without having to try to convince people to not use their electronic devices and electrically lit environments.
- 22:11And so just put up a couple of 20-person case series.
- 22:14Well, lo and behold, a colleague in Norway took this and did a randomized trial, which was published in 2016.
- 22:21The International Society for Bipolar Disorders said this was the most important paper of 2016.
- 22:28On an inpatient unit, people admitted with mild to moderate mania were randomized into blue blockers or control.
- 22:34And you can see what happens.
- 22:36In Norway, they were not being so aggressive about trying to get people unmanic.
- 22:40So even at the end of the week, they hadn't shifted all that much.
- 22:43Whereas the people who got the blue blocking lenses, everyone getting treatment as usual, including antipsychotics, but the blue blocker group only half as many antipsychotics,
- 22:52discharged from the hospital sooner.
- 22:54And as you can see, their scores coming down more quickly.
- 22:57Well, the reason I show you this is because this is the transformation in psychiatry.
- 23:01Look at this, what happened in Norway after this.
- 23:04They were building a brand new psychiatric unit at the time.
- 23:07Håvard Kallestad, who was in charge of this building project, a psychiatrist, said, "Hey, you know,
- 23:14we should take the opportunity, we should build two identical wings, one with no blue light environment and one with conventional lighting.
- 23:22And then we could do randomized trials because people get admitted to one and then the other unit in random sequence." So they actually have published now a randomized trial of
- 23:32what happens when people get admitted to this unit versus that unit.
- 23:36I think a remarkable achievement unto itself.
- 23:38Now they were going to use length of stay
- 23:41as one of the outcome measures, the primary outcome measure.
- 23:44There have been prior randomized trials of dark therapy, and length of stay was one of the outcome measures.
- 23:50So they were gonna use that too.
- 23:51But their length of stay on these units was so short that they really couldn't see a difference.
- 23:56But they also measured something called the Broset Checklist.
- 24:01This is a nursing checklist done at every shift, so three times every 24 hours.
- 24:06Patients were rated on this checklist for these six variables that are associated with violence, including actual violence, but also things that are associated with it.
- 24:17And the Broset Checklist scores over six months, looking at the two different units, you can tell there's gonna be a difference here, but look at the size of the difference:
- 24:26the scores of significant risk for violence, 73 versus eight on those two different units.
- 24:33So a huge difference that survived multiple efforts to check for other potential variables to explain it.
- 24:40But another facet of interest here is that this was not just applicable for people with bipolar.
- 24:45It was applicable for everybody who got admitted to that unit,
- 24:49except for the people who got admitted with depression, who served as kind of a control, if you will, where there was no difference in the events.
- 24:55It was everybody else showing this difference in potential liability for serious events on the units.
- 25:01So we have these data to support the idea that trying to help people understand more darkness before bedtime is a good idea.
- 25:11I think when you boil this down, it's a
- 25:14key part of social rhythm therapy.
- 25:16And if you haven't used this workbook yet, this is a very simple way to introduce yourself to SRT and immediately turn around and start using it with clients.
- 25:25That's the whole soup-to-nuts version of SRT.
- 25:29The really simplified version that I think gets a big chunk, maybe the biggest chunk, maybe the most important chunk of SRT,
- 25:37is simply to teach people to have a regular bedtime and a regular rise time, and to use calculated exposure to darkness and light as part of the way to help people get there to a
- 25:50regular bedtime and a regular rise time.
- 25:53Because as you know from clinical experience, just trying to help people get to a regular bedtime and a regular rise time can be a huge behavioral challenge.
- 26:02So you can help people get there
- 26:04with strategic use of darkness, including virtual darkness and light.
- 26:09I'll just point out that on my PsychEducation YouTube channel, this is about a 30-minute video because it's made for patients and families.
- 26:17The shtick that I just gave you on how to get to sleep control as a mood stabilizer using calculated use of light and darkness, that's all on that video.
- 26:27So you could save yourself
- 26:28the breath of doing that over and over again by pointing people to this video and I'm not making any money or selling anything on that YouTube channel.
- 26:35So what are the implications of this?
- 26:37Well, for one thing, not only does it show you that we can go from a mechanism to a treatment, and I think we're doing that for all of these, but it shows you the importance
- 26:45of teaching and facilitating a regular bedtime and a regular rise time.
- 26:50And by the way, if you're building an inpatient unit, you should build it with no blue light at night, built into the lighting system, if you happen to be doing that this week.
- 27:00In the meantime, let me check the chat.
- 27:02Tyler, thank you.
- 27:03Your question: Any particular type of blue blockers?
- 27:06On my website, depressioneducation.org, there's a page on light therapy and dark therapy.
- 27:12And the dark therapy page includes the whole shtick about blue blockers and includes the specific types that people can get that are very inexpensive, like $6, I think, for one of
- 27:25them and $13 for the fancier version.
- 27:28So people don't need to buy the $50 or $80 versions, they can buy something that costs $6 to $10.
- 27:33And so those are on my depressioneducation.org website.
- 27:36And you can use the search bar and look for "dark therapy" and you'll find that.
- 27:40Stephanie, you asked, "Should we all be wearing blue blockers since we have so much screen and computer time?" Not during the day, because during the day you want that blue light
- 27:49that's telling your super-chiasmatic nucleus that it's daytime.
- 27:53But at night,
- 27:54like starting around now on my end of the country, perhaps already on yours, yes.
- 28:00Now, some people are really sensitive to these things.
- 28:03Like when I was handing these out to my clients and patients, some people would come back and go, "Eh, this really didn't do anything." And in my experience, people will find out
- 28:13within four or five nights using them between say the hours of 8 p.m.
- 28:17and 10 p.m.
- 28:18because more than two hours, it's really hard to manage these things.
- 28:21About half the people would come back and say, "Eh, it didn't do anything." The other half came back and said, "It's amazing.
- 28:27I fall asleep about an hour earlier when I wear these things." So that's what you're looking for.
- 28:32And you can use that as a trial and say, "If they don't work, bring them back, I'll clean them up with some alcohol swabs and give it to somebody else."
- 28:39And you can try them yourself to see if it has an impact on your ability to fall asleep more quickly.
- 28:44There are a couple of randomized trials of using it just for insomnia and not for people with mood disorders that were positive trials.
- 28:51So yeah, point out to your colleagues that you shouldn't be wearing them during the day, only when you're trying to have real darkness.
- 28:58Now, some people who have super-sensitive nervous systems, including people who are somewhat
- 29:03neurodiverse in terms of their environmental stimulus sensitivity, might benefit from some blue blockade during the day.
- 29:13And they might even experiment with some of the blue blockers that are funkier, they're not such complete blue wavelength blockers, to see if they might be of benefit.
- 29:21How do you determine which patients might realistically benefit from interventions like ketogenic diet?
- 29:27Thank you for the question, Jamie.
- 29:29A ketogenic diet is difficult.
- 29:31It is inexpensive somewhat, but the food is somewhat more expensive than regular food.
- 29:36And there actually are some risks to really pursuing ketogenic diets, so it should be done
- 29:41with a physician's understanding of that this is going to be done.
- 29:44So there are some risks there.
- 29:45Whereas blue blockers are cheap, they are virtually harmless.
- 29:50One patient in that first Norwegian randomized trial got acutely depressed; came in manic, was in the blue blocker group, and got depressed.
- 29:58They took him out of the trial, stopped using the blue blockers, and he came right up out of that depression.
- 30:03They can be so powerful to take someone right out of a manic episode into a depressive episode.
- 30:09I think that's unusual with blue blockers, but we should be mindful of that potential.
- 30:14For some people, they could be really powerfully anti-manic and mood-stabilizing, because I think nearly anything that's clearly anti-manic is likely to be a mood stabilizer,
- 30:24although technically that needs another randomized trial to assert that.
- 30:28So the point was, and thank you, Dr.
- 30:30Wilson, for your question, some things are cheap and easy, and some things are challenging and potentially more expensive and maybe carry some risk.
- 30:38And so I would just sort those and help my client understand that these are potential options.
- 30:43And as you can gather, I think just trying to teach people to have a regular bedtime and a regular rise time is at the very top of that list.
- 30:51We're going to move on to this third transformation that I see coming here, which is the possibility that very low doses of lithium might prevent dementia.
- 31:01And the relevance here, particularly from a mood disorder specialist...
- 31:05And you may not be seeing people with minimal cognitive impairment necessarily, unless you're a gerontology specialist, which some of you may be.
- 31:14Trying to prevent dementia, that's obviously gonna be relevant for a huge swath of our aging population.
- 31:20But I think this is also of interest because if this turns out to be true, this will change the reputation of lithium.
- 31:27And if lithium's reputation was to change, then our practice, I hope, will change.
- 31:31So let's take a look at some of these data.
- 31:33If you just watch the red box, let me just scoot you through the population.
- 31:37So in 1950, this was the age distribution.
- 31:40In 2025, it looks like this.
- 31:42In 2050, it's going to look like that.
- 31:45So just going backwards, it goes *whoop* in the red box, we are an aging population.
- 31:50We all knew that.
- 31:51Well, what is a common age-associated life-threatening, life-quality-destroying...?
- 31:59Yeah, yeah, it's Alzheimer's.
- 32:01So if there was something that could prevent Alzheimer's, we certainly are interested for a variety of reasons.
- 32:07Well, let's take a look at this lithium story.
- 32:09You probably heard about this paper, published in the esteemed journal "Nature" from the Harvard team studying mice mostly, this is mostly about mice, there's a little human data
- 32:18in there.
- 32:19I've summarized this extremely important paper trying to translate it into basically plain English for your better-educated
- 32:26clients and their families who are interested in this, including you, because trying to wade through that paper is a huge challenge.
- 32:34It took hours because "Nature," the journal, only allows you to have five figures.
- 32:39And yet people who publish in Nature are publishing the results of 30, 40, 50 experiments, as this group did.
- 32:46Well, how do you jam all that in there?
- 32:48Oh, well, you have five or six figures per figure.
- 32:52There's like 40 figures in this paper.
- 32:54Let me just show you the two main findings that come out of this.
- 32:57The first is addressing this question: Could lithium prevent progression to Alzheimer's?
- 33:02Well, we're going to look mostly at data in mice, although they look briefly at some data in humans.
- 33:06And this is what we're trying to do is prevent progression.
- 33:10In other words, you would potentially start lithium before the onset of any minimal cognitive impairment.
- 33:16Is that logical?
- 33:18Data-based?
- 33:19Is there anything to suggest that this might be worth considering like even now?
- 33:24Well, in a mouse, there's a mouse model of Alzheimer's.
- 33:28It isn't perfect.
- 33:29So the analog here is not perfect, but they do form amyloid plaque just like humans do when humans develop Alzheimer's.
- 33:37And they also phosphorylate tau and their tau proteins turn into tau tangles just like humans.
- 33:43So in those respects,
- 33:45the Alzheimer's mouse is a somewhat good model.
- 33:48It's what we have.
- 33:49Well, what they did was take Alzheimer's-prone mice that were genetically bred to have that predilection and greeted them with low doses of lithium, two different kinds of
- 34:00lithium.
- 34:00Lithium carbonate, which is, as you know, the one we've been prescribing all this last 50 years,
- 34:06and lithium orotate.
- 34:08And lithium orotate is selected because they thought it might be less vulnerable to getting sequestered in those amyloid plaques, which turns out to be the fate of lithium in
- 34:17the brain, according to other data in this paper.
- 34:20So they're going to compare lithium carbonate and lithium orotate in the Alzheimer's mouse.
- 34:25Here's the key study and I'll show you the data from this one because it's so important.
- 34:29Here's the control mouse who is fed only water, typical water, regular water, no lithium in their water.
- 34:36And the plaque burden they developed by old age, as you can see in the immunofluorescent stain and their plaque burden.
- 34:44They're the control.
- 34:45So their plaque burden is 100% of control, they are the controls.
- 34:48Well, imagine what that bar is gonna look like or the fluorescent stain
- 34:53for the mice that got lithium.
- 34:55Where's that bar gonna go?
- 34:57Well, those who got lithium orotate in their water from early adulthood, because we're trying to prevent this plaque development, here's what their plaque burden looks like.
- 35:07Like that, like close to zero.
- 35:10That is the key finding from this paper, the first of two.
- 35:14They checked several different doses of lithium orotate, two other higher doses, with pretty much the same results.
- 35:22They also looked at lithium carbonate, because lithium carbonate has been studied in several randomized trials for the prevention of dementia.
- 35:29And it turns out, oops, lithium carbonate doesn't work so well.
- 35:33So maybe lithium orotate, at least in the mouse model, clearly works better than lithium carbonate.
- 35:39What dose?
- 35:40Well,
- 35:40we don't know what the right dose is because they didn't use a dose that was low enough to show you that it didn't work.
- 35:48We don't know where the bottom of this progression is yet.
- 35:50I hope someone will turn around and do that.
- 35:53But for the moment, we know that 4.3 micro equivalents per liter in the mouse water was enough to get this stunning result.
- 36:01If you were to ask me, what's the human equivalent of that?
- 36:05It's actually 0.5 milligrams of lithium orotate per day is the human dose equivalent for an 80-kilogram person for that mouse dose.
- 36:15What does that mean?
- 36:16We don't know.
- 36:17There are no studies of lithium orotate for the prevention of dementia in humans, but we know plenty of people have been taking lithium orotate for a long time.
- 36:25So we know that it appears to be quite safe.
- 36:28And I'll talk about that more in just a moment.
- 36:30Lithium carbonate?
- 36:31Not so good.
- 36:31As far as the phosphorylation of tau and the tau proteins that we know is part of the pathophysiology in human Alzheimer's, same exact story here,
- 36:41including with lithium carbonate, not so effective.
- 36:44What do we conclude from all of this?
- 36:46Well, wait a minute.
- 36:46There's one other facet of this study.
- 36:49And that is that lithium might actually have the potential to reverse already established minimal cognitive impairment.
- 36:58How do we know this?
- 36:59Well, in a mouse, if you put them in a swim tank, they don't like that.
- 37:02If there's a platform there, they'll swim to it.
- 37:04And if they do this six days in a row, they'll learn where that platform is and swim straight to it.
- 37:10Whereas the Alzheimer's mouse, sorry, doesn't remember where the platform is and swims all over the place.
- 37:16So we can use swim time as a marker for memory.
- 37:21The more time they spend on the platform, the target area, the better their memory.
- 37:25If we look at the wild type mouse, they spend this much time in the target area, the wild type meaning they're not even Alzheimer's-prone, so they don't have Alzheimer's.
- 37:35So this is our control mouse.
- 37:36Three different Alzheimer's-prone mice, some that get lithium and some that don't.
- 37:41The first group that just got water, but they're Alzheimer's-prone, you can see, this is the fate of an Alzheimer's mouse.
- 37:47They don't remember where the platform is.
- 37:49They spend more time swimming.
- 37:50Those who got lithium orotate, now not from early age, but from late middle age in a mouse, sort of like 55, 60 in a human roughly.
- 38:01Hard to make that analogy, but just to give us a ballpark, those who got the lithium orotate, how much time did they spend swimming around?
- 38:09They're much more like the control mouse,
- 38:11the not-Alzheimer's-susceptible mouse.
- 38:15And lithium carbonate, same as the plaque prevention, didn't work so well.
- 38:20So I think the implications of that are clear and I'll just skim over that to say we really need to be thinking about lithium now, not only for the prevention of Alzheimer's,
- 38:29but even for the potential treatment of it.
- 38:32Because the other treatments are scary and we don't have much else.
- 38:36And it's a disastrous condition, Alzheimer's.
- 38:39I think thinking about lithium for the treatment of minimal cognitive impairment now is even a candidate potential.
- 38:46So I wrote all that stuff up on my YouTube channel, if you want to pursue any of those or send patients and clients there.
- 38:54I don't make any money from any of these things, either.
- 38:56And that then is my presentation for this evening.
- 38:59George, can you turn off mute and say hello and...
- 39:04Any thoughts or comments before I pick up something from the chat?
- 39:08Hello everyone and thank you, Jim, for a wonderful presentation.
- 39:12Some really exciting developments.
- 39:14I think they're very, very useful to, really, all mental health professionals, particularly the idea of thinking dimensionally, which is something we've been seeing in
- 39:24our clinical population.
- 39:25And I think many of us have probably been thinking that way anyway, but like you said, the diagnostic system is
- 39:31now beginning to catch up with what I think may have been the practice of many clinicians.
- 39:36So, incredibly useful developments.
- 39:39I do want to mention that Dr.
- 39:41Phelps and I will be presenting this year at the American Psychological Association convention in August.
- 39:48So if you are going to be attending, we would love to see you there.
- 39:52We will be talking a little bit more about mixed bipolar and we'll mention some of the developments that we've talked about here.
- 40:00And one of the things I thought about while you were talking about blue light is...
- 40:05First, so many people use screens before they go to sleep.
- 40:11These tend to be pretty heavy on blue light, but there are filters that people can install,
- 40:19which can really diminish the amount of blue light.
- 40:22And from my own practice, because I do so much work with kids and teenagers, I immediately thought about the importance of parents being very proactive about helping kids develop
- 40:35healthy habits and consistent bedtimes.
- 40:38And modeling, that they too can model avoiding exposure to blue light at night.
- 40:43And as you point out, it filters out the level of the TV or your handhelds and just getting a no blue emitting light bulb.
- 40:52So you could have the rooms that you use late at night just have no blue come out of their light bulb.
- 40:57There's another way to do it without the glasses.
- 40:59Dr.
- 41:00Miller asked a very important question.
- 41:02How have you factored out or in chronic trauma?
- 41:05The answer is, you could say it's really complicated actually, but the simple version is when people have both bipolarity and a trauma history, trying to treat the trauma history
- 41:15without having addressed bipolar mood stability, I think is going uphill.
- 41:20So treating whatever bipolar component might be there first and then trying to address trauma, I think is a much easier way of going about it with some potential exceptions
- 41:30granted.
- 41:31Moreover, trying to separate out the two...
- 41:34Is this depression with PTSD?
- 41:36Or is this bipolar mixed state with, as Roger McIntyre calls it, the four A's, anxiety, anger, agitation, and attention problems.
- 41:49Is this depression plus anxiety and anger and attention problems?
- 41:54Is it depression plus PTSD?
- 41:57Is the depression plus ADHD?
- 41:59Is it depression plus GAD?
- 42:00Is it depression in borderlinity?
- 42:03Or is it a bipolar mixed state?
- 42:06That diagnostic differential, if you just look at symptoms, is nearly impossible.
- 42:12All of those four variations, PTSD, ADHD, GAD, and borderline, all have nearly all the same symptoms as depression
- 42:21and bipolar with mixed features: anxiety, agitation, attention problems, and anger.
- 42:27So how can you manage if all the symptoms are basically almost 100% overlap?
- 42:32And the answer is there are four other factors that help detect bipolarity: Age of onset of first depression, family history, course of illness, meaning how cyclic is it, and
- 42:45response to treatment,
- 42:46mainly like adverse responses to antidepressants.
- 42:49Age of onset, family history, course of illness, response to treatment.
- 42:53We should make those four things part of our routine assessment of bipolarity and depression in order to differentiate PTSD, GAD, ADHD, and borderlinity.
- 43:05It's a long version, but I hope you see that the maneuver is simple.
- 43:11The practice is very, very complicated, as you know.
- 43:14But the logic and the maneuver is pretty simple.
- 43:17For clinicians interested in learning more about low-dose lithium and lithium orotate, reputable sourcing?
- 43:22I put more on that PsychEducation YouTube channel and there's a playlist about dementia and lithium.
- 43:28I've put more there than I found anywhere else and I've been very careful about differentiating opinion from data.
- 43:35And so starting with just the plain English translation of the "Nature" paper,
- 43:40I think is a really important starting place in terms of understanding in mice, this is what we have observed.
- 43:46So even though it's my stuff, that's where I'd go first.
- 43:50There is a lithium orotate page on my website as well.
- 43:52And then you could say, okay, after that, what else?
- 43:55OpenEvidence.com is an AI-supported way to browse the literature.
- 44:00I think I'd turn and go there because it goes in the National Library of Medicine and treatment guideline databases and stays away from potential AI hallucinations.
- 44:10Over-the-counter variability as part of that question about lithium orotate, that's a huge potential problem.
- 44:16Just to see something, if you let AI search, you can't get it if you go to Consumer Labs directly, but AI will search their database and steal their report on about five different
- 44:28versions of lithium orotate that met Consumer Labs' standards for there really is lithium in there.
- 44:35And there are no other trace elements that could be concerning.
- 44:37And one of those is KAL, and one of them is something else.
- 44:42But if you just use Google AI and search "lithium orotate independent laboratory examination of contents," something like that, you'll probably get that Consumer Labs
- 44:55list.
- 44:55KAL is one of them,
- 44:58which was a relief to me because that's the one that I'm buying from my local grocery store in case you were wondering, am I taking it?
- 45:03Well, you betcha.
- 45:04If I'm this enthusiastic about it, you'd think that I ought to be, yes.
- 45:08Dr.
- 45:08Fogle asks, "If dimensions are going to be considered in DSM-5, what is the likelihood that the new one actually includes it?" Well, good question because that paper that I
- 45:19referenced from January in the American Journal of Psychiatry, that's just the team that's being invited to consider this.
- 45:26That is not necessarily, "we're going to do this." But I think they've committed themselves so far in that direction.
- 45:32I think from my read of that article, have a look, I think there's full text online.
- 45:36I think it looks pretty likely because all they're doing is gonna say, yeah, both of these are valuable, both dimensional and categorical.
- 45:46And, no, I think cynicism in this territory is highly, highly warranted.
- 45:52And we're not gonna switch to a dimensional system.
- 45:54We're just gonna edit alongside a dimensional system
- 45:57and the weight of the DSM carrying us back into yes or no, you have it or you don't.
- 46:02I think your cynicism is highly warranted, but at least in my view, this is progress.
- 46:09All right.
- 46:09Thank you all for attending.
- 46:10Thank you for the opportunity to talk with you.
- 46:12And George, thanks for setting this up.
- 46:14Bye now.
- 46:15Thanks, Jim.
- 46:15We'll see you next time.